313 related articles for article (PubMed ID: 32910913)
41. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
[TBL] [Abstract][Full Text] [Related]
42. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
[TBL] [Abstract][Full Text] [Related]
43. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
44. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts.
Mirshahi UL; Colclough K; Wright CF; Wood AR; Beaumont RN; Tyrrell J; Laver TW; Stahl R; Golden A; Goehringer JM; ; Frayling TF; Hattersley AT; Carey DJ; Weedon MN; Patel KA
Am J Hum Genet; 2022 Nov; 109(11):2018-2028. PubMed ID: 36257325
[TBL] [Abstract][Full Text] [Related]
45. Functional characterization of HNF4A gene variants identify promoter and cell line specific transactivation effects.
Kaci A; Solheim MH; Silgjerd T; Hjaltadottir J; Hornnes LH; Molnes J; Madsen A; Sjøholt G; Bellanné-Chantelot C; Caswell R; Sagen JV; Njølstad PR; Aukrust I; Bjørkhaug L
Hum Mol Genet; 2024 May; 33(10):894-904. PubMed ID: 38433330
[TBL] [Abstract][Full Text] [Related]
46. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
[TBL] [Abstract][Full Text] [Related]
47. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
Ellard S; Thomas K; Edghill EL; Owens M; Ambye L; Cropper J; Little J; Strachan M; Stride A; Ersoy B; Eiberg H; Pedersen O; Shepherd MH; Hansen T; Harries LW; Hattersley AT
Diabetologia; 2007 Nov; 50(11):2313-7. PubMed ID: 17828387
[TBL] [Abstract][Full Text] [Related]
48. The spectrum of HNF1A gene mutations in patients with MODY 3 phenotype and identification of three novel germline mutations in Turkish Population.
Karaca E; Onay H; Cetinkalp S; Aykut A; Göksen D; Ozen S; Atik T; Darcan S; Tekin IM; Ozkınay F
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S491-S496. PubMed ID: 28395978
[TBL] [Abstract][Full Text] [Related]
49. The contribution of functional HNF1A variants and polygenic susceptibility to risk of type 2 diabetes in ancestrally diverse populations.
Stalbow LA; Preuss MH; Smit RAJ; Chami N; Bjørkhaug L; Aukrust I; Gloyn AL; Loos RJF
Diabetologia; 2023 Jan; 66(1):116-126. PubMed ID: 36216889
[TBL] [Abstract][Full Text] [Related]
50. HNF1A-MODY Mutations in Nuclear Localization Signal Impair HNF1A-Import Receptor KPNA6 Interactions.
Fareed FMA; Korulu S; Özbil M; Çapan ÖY
Protein J; 2021 Aug; 40(4):512-521. PubMed ID: 33459938
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study).
Eide SA; Raeder H; Johansson S; Midthjell K; Søvik O; Njølstad PR; Molven A
Diabet Med; 2008 Jul; 25(7):775-81. PubMed ID: 18513305
[TBL] [Abstract][Full Text] [Related]
52. Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young.
Tijardović M; Štambuk T; Juszczak A; Keser T; Gasperikova D; Novokmet M; Tjora E; Pape Medvidović E; Stanik J; Rasmus Njølstad P; Lauc G; Owen KR; Gornik O
Diabetes Res Clin Pract; 2022 Mar; 185():109226. PubMed ID: 35122907
[TBL] [Abstract][Full Text] [Related]
53. Identification of novel variants in the hepatocyte nuclear factor-1alpha gene in South Indian patients with maturity onset diabetes of young.
Radha V; Ek J; Anuradha S; Hansen T; Pedersen O; Mohan V
J Clin Endocrinol Metab; 2009 Jun; 94(6):1959-65. PubMed ID: 19336507
[TBL] [Abstract][Full Text] [Related]
54. Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy.
Tatsi EB; Kanaka-Gantenbein C; Scorilas A; Chrousos GP; Sertedaki A
Pediatr Diabetes; 2020 Feb; 21(1):28-39. PubMed ID: 31604004
[TBL] [Abstract][Full Text] [Related]
55. Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes.
Juszczak A; Pavić T; Vučković F; Bennett AJ; Shah N; Pape Medvidović E; Groves CJ; Šekerija M; Chandler K; Burrows C; Rojnić Putarek N; Vučić Lovrenčić M; Ćuća Knežević J; James TJ; Gloyn AL; Lauc G; McCarthy MI; Owen KR; Gornik O
Diabetes Care; 2019 Jan; 42(1):17-26. PubMed ID: 30455330
[TBL] [Abstract][Full Text] [Related]
56. Genetic testing for maturity-onset diabetes of the young resulting in an upgraded genetic classification of an HNF1A gene variant: a case report.
Pollack-Schreiber N; Nwosu BU; Salemi P
Front Endocrinol (Lausanne); 2023; 14():1173471. PubMed ID: 37396173
[TBL] [Abstract][Full Text] [Related]
57. Identification of candidate gene variants of monogenic diabetes using targeted panel sequencing in early onset diabetes patients.
Lee DH; Kwak SH; Park HS; Ku EJ; Jeon HJ; Oh TK
BMJ Open Diabetes Res Care; 2021 Jun; 9(1):. PubMed ID: 34135026
[TBL] [Abstract][Full Text] [Related]
58. Development of an exoglycosidase plate-based assay for detecting α1-3,4 fucosylation biomarker in individuals with HNF1A-MODY.
Demus D; Urbanowicz PA; Gardner RA; Wu H; Juszczak A; Štambuk T; Medvidović EP; Owen KR; Gornik O; Juge N; Spencer DIR
Glycobiology; 2022 Mar; 32(3):230-238. PubMed ID: 34939081
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY.
Laver TW; Wakeling MN; Knox O; Colclough K; Wright CF; Ellard S; Hattersley AT; Weedon MN; Patel KA
Diabetes; 2022 May; 71(5):1128-1136. PubMed ID: 35108381
[TBL] [Abstract][Full Text] [Related]
60. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.
Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D
PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
